<DOC>
	<DOCNO>NCT00879528</DOCNO>
	<brief_summary>PET-based consolidation donor-based therapy rescue patient Hodgkin 's lymphoma refractory first line therapy , relapse early late , undergone second line chemotherapy .</brief_summary>
	<brief_title>Consolidation PET-based Donor-based After Salvage Therapy Patients With HL Relapse Refractory</brief_title>
	<detailed_description>This prospective observational study patient positive PET scan salvage therapy candidate sequential scheme `` auto-allotransplantation '' case availability donor . In event unavailability donor , patient candidate double high-dose chemotherapy autologous stem cell support .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Patients confirm Hodgkin 's lymphoma refractory first line therapy , relapse early late ; Age &gt; 18 year ; Life expectancy &gt; 3 month ; Cardiac , pulmonary , renal liver function normal range ; Written inform consent . Any psychological , familiar geographical condition could potentially hinder compliance protocol ; renal failure creatinine &gt; 1.2 mg/dl creatinine clearance &lt; 60 ml/min ; AST/ALT bilirubin &gt; 2.5 time norm ; HCV positivity sign ongoing viral replication ( HCV PCR + AST &gt; 1.52x normal ) ; Heart disease clinically significant : eg . severe hypertension control , multifocal uncontrolled cardiac arrhythmia , symptomatic ischemic heart disease congestive heart failure class NYHA class IIIIV ( Annex 2 ) , previous acute myocardial infarction ; Ventricular ejection fraction &lt; 45 % ; decompensated diabetes mellitus control insulin therapy ; Disease significant pulmonary function define FEV1 &lt; 65 % predict DLCO &lt; 50 % predict value ; HIV positive patient ; Patients uncontrolled infection ; Neoplasia last 3 year except carcinoma situ uterus , neck basal skin cancer prostate cancer early stage localize exeresi treat surgery brachytherapy curative intent , good prognosis DCIS breast treat surgery alone ; Drug addiction alcoholism .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>stem cell reinfusion</keyword>
</DOC>